APPARENT HEPARIN RESISTANCE FROM ELEVATED FACTOR VIII DURING PREGNANCY

2000 ◽  
Vol 96 (Supplement) ◽  
pp. 804-806
Author(s):  
Robert A. Raschke ◽  
James R. Guidry ◽  
Michael R. Foley
2021 ◽  
Vol 41 (3) ◽  
pp. 33-41
Author(s):  
Lisa Fetters ◽  
Sue Sirianni

Introduction Heparin resistance was discovered in a patient in the surgical intensive care unit who underwent emergency endovascular coiling and later an anterior communicating artery clipping procedure to treat subarachnoid hemorrhage due to rupture of an anterior communicating artery aneurysm. Clinical Findings On intensive care unit day 17/postoperative day 3, the patient experienced shortness of breath, persistent tachycardia, and hypoxia. Bilateral pulmonary emboli, a saddle embolus, and lower-extremity and upper-extremity deep vein thrombi were diagnosed. The patient received high-dose unfractionated heparin (>35 000 U/24 h), and activated partial thromboplastin times remained subtherapeutic over the next 72 hours. Diagnosis Factor VIII activity, fibrinogen, antithrombin activity, antithrombin antigen, and platelet factor 4 were measured. The results demonstrated an increase in factor VIII activity to 342% (reference range, 50%-200%), elevated fibrinogen level of 441 mg/dL (reference range, 200-400 mg/dL), antithrombin antigen level of 92% (reference range, 80%-130%), elevated antithrombin activity of 108% (reference range, 80%-100%), and negative platelet factor 4 result, indicating that the patient did not have heparin-induced thrombocytopenia and confirming the diagnosis of heparin resistance. Conclusions Risk factors for heparin resistance include antithrombin deficiency, elevation of factor VIII or fibrinogen level, elevation in heparin-binding proteins, increased heparin clearance, sepsis, trauma, and burns. The astute critical care nurse may be the first to recognize this condition in a patient, preventing a potentially fatal complication.


Author(s):  
Antti I. Nykänen ◽  
Rita Selby ◽  
Karen M. McRae ◽  
Yidan Zhao ◽  
Usman M. Asghar ◽  
...  

2019 ◽  
pp. 089719001988523 ◽  
Author(s):  
Janelle O. Poyant ◽  
Augustus M. Gleason

Background: Argatroban, a synthetic, parenteral, nonheparin anticoagulant, is a direct thrombin inhibitor indicated for the prophylaxis or treatment of venous thromboembolism (VTE) in patients with heparin-induced thrombocytopenia with thrombosis (HITT) and for use during percutaneous coronary intervention (PCI) in patients who have or are at risk for developing HITT. Although heparin resistance occurs in approximately 0.5% to 5% of heparin-treated patients and is well documented in the literature, argatroban resistance is limited to a single case report. The objective of this case is to describe a case in which argatroban resistance was suspected in a patient with critical limb ischemia. Methods: This is a case report of a single patient. Results: A 68-year-old female admitted for critical limb ischemia requiring vascular intervention was treated for presumed HITT with argatroban. A therapeutic activated partial thromboplastin time (aPTT) was not attained (31 seconds) despite multiple uptitrations of the dose to 2.8 μg/kg/min (adjusted based on the institutional protocol and with consideration of organ dysfunction). A coagulopathy workup revealed a high level of factor VIII (265%). Conclusion: This case supports early assessment of factor VIII levels and the consideration of argatroban resistance and in patients who have a subtherapeutic aPTT, despite multiple increases in dose with an elevated factor VIII level. Early identification should prompt the use of an alternative anticoagulant to ensure efficacy.


2019 ◽  
Vol 66 (8) ◽  
pp. 995-996 ◽  
Author(s):  
Ian Downie ◽  
Zachary Liederman ◽  
Kartiga Thiyagarajah ◽  
Rita Selby ◽  
Yulia Lin

2000 ◽  
Vol 111 (1) ◽  
pp. 78-90 ◽  
Author(s):  
C. R. M. Hay ◽  
T. P. Baglin ◽  
P. W. Collins ◽  
F. G. H. Hill ◽  
D. M. Keeling

Haemophilia ◽  
2001 ◽  
Vol 7 (4) ◽  
pp. 364-368 ◽  
Author(s):  
E. P. Mauser-Bunschoten ◽  
J. G. Van Der Bom ◽  
M. Bongers ◽  
M. Twijnstra ◽  
G. Roosendaal ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document